A combination of scGOS/lcFOS with Bifidobacterium breve M-16V protects suckling rats from rotavirus gastroenteritis

M Rigo-Adrover1,2, S Saldaña-Ruíz1,2, K van Limpt3

  • 1Department of Physiology, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.

Insights

A daily prebiotic and probiotic supplement effectively reduced rotavirus (RV) diarrhea in infant rats. Both interventions modulated immune responses and reduced viral shedding, offering a promising strategy for managing RV infections.

Area of Science:

  • Gastroenterology
  • Microbiology
  • Immunology

Background:

  • Rotavirus (RV) is a primary cause of severe infant diarrhea.
  • Probiotics show potential against RV and other intestinal issues.
  • Prebiotic effects on RV infection require further investigation.

Purpose of the Study:

  • To evaluate the protective effects of a specific prebiotic mixture (scGOS/lcFOS 9:1), Bifidobacterium breve M-16V (probiotic), and their combination (synbiotic) in a rat model of RV infection.

Main Methods:

  • Suckling rats received oral gavage of prebiotic, probiotic, or synbiotic from day 3 to 21.
  • Rotavirus was administered on day 7.
  • Clinical parameters and immune responses were assessed.

Main Results:

  • Probiotic intervention decreased diarrhea incidence, severity, and duration.
  • Prebiotic and synbiotic interventions also improved clinical parameters and significantly reduced viral shedding.
  • All interventions modulated specific antibody responses in serum and intestinal washes.

Conclusions:

  • Daily supplementation with the scGOS/lcFOS 9:1 prebiotic mixture, Bifidobacterium breve M-16V, or their combination is highly effective in mitigating RV-induced diarrhea in a preclinical model.
Abstract

Related Concept Videos

Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
10
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
9
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
9